Phase 3 Recruiting NIH
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Virginia: - Ballad Health Cancer Care - Bristol — Bristol, Virginia
- Kaiser Permanente-Burke Medical Center — Burke, Virginia
- University of Virginia Cancer Center — Charlottesville, Virginia
- Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
- Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Virginia: - Local Institution - 007-814-A — Alexandria, Virginia
- Local Institution - 007-814-D — Arlington, Virginia
- USOR - Virginia Cancer Specialists - Fairfax Office — Fairfax, Virginia
- Local Institution - 007-814-B — Gainesville, Virginia
- Local Institution - 007-814-C — Leesburg, Virginia
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Virginia: - UVA Comprehensive Cancer Center — Charlottesville, Virginia
- UVA Health Fontaine Research Park — Charlottesville, Virginia
- University of Virginia — Charlottesville, Virginia
- UVA Health Cancer Care Pantops — Charlottesville, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …
Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
- USO - Virginia Cancer Specialists — Fairfax, Virginia
- VCU Health Adult Outpatient Pavillion — Richmond, Virginia
Phase 3 Recruiting Industry
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Virginia: - Clinical Study Site — Blacksburg, Virginia
- Clinical Study Site — Charlottesville, Virginia
- Clinical Study Site — Fairfax, Virginia
- Clinical Study Site — Richmond, Virginia
- Clinical Study Site — Richmond, Virginia
Phase 3 Recruiting Industry
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…
Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
- VCU Health Adult Outpatient Pavillion — Richmond, Virginia
Phase 3 Recruiting Industry
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…
Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Virginia: - Virginia Oncology Associates — Norfolk, Virginia
- Virginia Cancer — Reston, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Virginia: - Inova Alexandria Hospital — Alexandria, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fair Oaks Hospital — Fairfax, Virginia
- Inova Loudoun Hospital — Leesburg, Virginia
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Virginia: - Virginia Cancer Specialists ( Site 0167) — Fairfax, Virginia
- Virginia Oncology Associates (VOA) ( Site 8101) — Norfolk, Virginia
- VCU Health Adult Outpatient Pavillion ( Site 0193) — Richmond, Virginia
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Virginia: - Local Institution - 0131 — Fairfax, Virginia
- Virginia Commonwealth University — Richmond, Virginia
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
- Inova Fairfax Medical Campus — Falls Church, Virginia
Phase 3 Recruiting Industry
This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Sponsor: AstraZeneca
NCT ID: NCT06417814
Sites in Virginia: - Research Site — Fairfax, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 3 Recruiting Academic/Other
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has …
Sponsor: Pfizer
NCT ID: NCT07226999
Sites in Virginia: - Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Blacksburg, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Low Moor, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Roanoke, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Salem, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Wytheville, Virginia
Phase 3 Recruiting Industry
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants …
Sponsor: ArriVent BioPharma, Inc.
NCT ID: NCT07185997
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
- Virginia Cancer Specialists — Fairfax, Virginia
- Shenandoah Oncology, P.C. — Winchester, Virginia
Phase 3 Recruiting Industry
The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in…
Sponsor: Nuvation Bio Inc.
NCT ID: NCT07154706
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 2 Recruiting Network
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Virginia: - Kaiser Permanente Tysons Corner Medical Center — McLean, Virginia
- Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia
Phase 2 Recruiting Industry
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 2 Recruiting Industry
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT04614103
Sites in Virginia: - VCU Medical Center (Virginia Commonwealth University) — Richmond, Virginia
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study…
Sponsor: AbbVie
NCT ID: NCT06568939
Sites in Virginia: - Virginia Cancer Specialists - Fairfax /ID# 272004 — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 2 Recruiting Industry
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06095505
Sites in Virginia: - Oncology & Hematology Associates of Southwest Virginia — Blacksburg, Virginia
- Universtity of Virginia Health System — Charlottesville, Virginia
- Virginia Cancer Specialists Research Institute — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread bey…
Sponsor: Pfizer
NCT ID: NCT07227298
Sites in Virginia: - VCU Medical Center Gateway Building — Richmond, Virginia
- Virginia Commonwealth University — Richmond, Virginia
- VCU Health Stony Point — Richmond, Virginia
- Massey Cancer Center Clinical & Translational Research Lab — Richmond, Virginia
- Virginia Commonwealth University — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 wi…
Sponsor: BlossomHill Therapeutics
NCT ID: NCT06706076
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia